Jeremy R. Graff - 28 Jan 2026 Form 4/A - Amendment Insider Report for Allarity Therapeutics, Inc. (ALLR)

Reporting relationship: President and Chief Development Officer
Issuer ticker: ALLR
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 30 Apr 2026, 15:38:10 UTC
Original report date: 16 Jan 2026
Prior SEC filing: 16 Jan 2026
Next SEC filing: 12 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeremy R. Graff

Key filing fact

Jeremy R. Graff filed Form 4/A - Amendment for Allarity Therapeutics, Inc. (ALLR) on 30 Apr 2026.

Key facts

This page summarizes Jeremy R. Graff's Form 4/A - Amendment filing for Allarity Therapeutics, Inc. (ALLR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Apr 2026, 15:38.

Change

Previous filing in this sequence was filed on 16 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001975028 Primary reporting owner

Graff Jeremy R.

Relationship: President and Chief Development Officer
Address: C/O ALLARITY THERAPEUTICS, INC., 123 E TARPON AVE, TARPON SPRINGS
Signature: /s/ Jeremy R. Graff
Signature date: 30 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLR transaction

Common Stock

Award

Transaction value
Shares: +133,333
Change %: +54%
Price: $0.000000^*
Shares after: 381,644
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

SEC remarks

President and Chief Development Officer